Skip to Content

Amgen Inc AMGN Stock Quote

| Rating as of


Morningstar‘s Stock Analysis AMGN

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Maintaining Our $255 Amgen FVE Following Steady 3Q; Price and Competition Constrain Growth

Karen Andersen Sector Strategist

Analyst Note

| Karen Andersen |

Amgen’s third-quarter revenue fell 1% from the prior-year period, as pricing pressure and foreign-exchange headwinds countered the 8% volume growth in the quarter. Non-GAAP net income grew 15% largely because of a $400 million up-front payment to Kyowa Kirin for atopic dermatitis drug AMG 451 in the third quarter of 2021 (excluding this payment from non-GAAP results implies 1% non-GAAP net income growth for the quarter). While Amgen’s osteoporosis business (Prolia and Evenity) continues to stabilize Amgen’s results, we’re less enthusiastic about growth prospects for Amgen’s other established drugs. We look to the launch of Amjevita (Humira biosimilar) in 2023 as well as the continuing launches of lung cancer drug Lumakras and asthma drug Tezspire to help drive growth heading into next year, and we’re particularly bullish on Tezspire’s differentiated profile from Regeneron/Sanofi’s Dupixent and strong efficacy. The drug was also just approved in Europe and Japan in September, and several studies in other immunology indications are in progress that could further expand its potential. In addition, the recent acquisition of ChemoCentryx and immunology drug Tavneos should prove complementary to Amgen’s existing immunology business. We think these newer products will help keep Amgen’s wide moat secure, and we’re maintaining our $255 fair value estimate.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics AMGN

Company Profile AMGN

Business Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

One Amgen Center Drive
Thousand Oaks, CA, 91320-1799
Industry Drug Manufacturers - General
Employees 24,200

Related Articles AMGN

FAQs for Amgen Inc Stock

Yes. AMGN has a forward dividend yield of 2.74%. See AMGN’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

AMGN’s market cap is 151.92 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

AMGN’s stock style is Large Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

AMGN’s price/sales is 5.89.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

AMGN’s price/forward earnings is 15.27.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

AMGN’s price/book is 41.38.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See AMGN’s valuation ratios compared to the Market Index.

AMGN’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare AMGN’s historical performance against its industry peers and the overall market.